

## **No Impact of Hepatitis B Virus Infection on Early Mortality among HIV-infected Patients in Southern Africa**

**(Reply to Kouamé et al. *Clin Infect Dis* 2018)**

Running title: Early mortality in HIV/HBV-coinfection

Jonas Hector<sup>1</sup>, Michael Vinikoor<sup>2,3</sup>, Roma Chilengi<sup>2</sup>, Jochen Ehmer<sup>1</sup>, Matthias Egger<sup>4,5</sup>, Gilles Wandeler<sup>5,6</sup>, for leDEA-Southern Africa

<sup>1</sup> SolidarMed, Ancuabe, Mozambique.

<sup>2</sup> Centre for Infectious Disease Research in Zambia, Lusaka, Zambia.

<sup>3</sup> Department of Medicine at University of Alabama, Birmingham, United States of America.

<sup>4</sup> School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

<sup>5</sup> Institute of Social & Preventive Medicine (ISPM), University of Bern, Switzerland.

<sup>6</sup> Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland.

Corresponding author: Jonas Hector, SolidarMed 16 Av Marginal Bairro de Cimento, Pemba, Cabo Delgado, Mozambique; E-mail: [j.hector@solidarmed.ch](mailto:j.hector@solidarmed.ch)

Alternate corresponding author: Gilles Wandeler, Inselspital, Universitätsspital Bern, Department of Infectious Diseases, Freiburgstrasse CH-3010 Bern, Switzerland, E-mail: [gilles.wandeler@insel.ch](mailto:gilles.wandeler@insel.ch)

Key words: HIV, Hepatitis B infection, Mortality, Sub-Saharan Africa.

DEAR EDITOR, We read with interest the informative article by Kouamé et al. describing mortality in HIV/Hepatitis B virus (HBV)-coinfected patients on antiretroviral therapy (ART) in West Africa (1). In line with studies from high-income countries, the results from the Temprano trial show that active HBV infection increases mortality among HIV-infected individuals (2). However, clinical trial data cannot be generalized to other clinical settings in sub-Saharan Africa (SSA), where resources for patient monitoring and management are limited and patient who initiate ART have often present with advanced stages of disease and comorbidities. Real-life data on the impact of HBV determinants on mortality from primary HIV care settings in SSA are scarce.

Since January 2013, we recruited consecutive HIV-infected patients at time of ART initiation into a prospective cohort in Lusaka, Zambia, and Ancuabe, a rural area in Mozambique, within the leDEA collaboration (3). All patients were tested for the presence of chronic HBV infection, defined as a positive HBsAg rapid test (Determine<sup>®</sup>, Alere, Yavne, Israel), and HBV viral load (VL) was measured in HIV/HBV-coinfected individuals using quantitative real-time polymerase chain reaction (Roche, Indianapolis, USA) from plasma or dried blood spots (4). The systematic tracing of patients lost to follow-up (LTFU, ie. >3 months without a clinical visit) during the first year of ART was performed by phone calls or home visits. We used multivariable Cox proportional hazard methods to compare one-year mortality between HBV-infected and uninfected patients.

Fourteen percent (276/1,948) of the study participants were HBsAg-positive, of whom 137 (49.6%) had an HBV VL above 2000 IU/ml. Median age was 32 years (interquartile range [IQR] 26-40 years), median CD4 count 252 cells/ $\mu$ l (IQR 130-369), 38% had WHO stage 3 or 4, and 36% were female. There were no significant differences in CD4 cell counts, body mass index, age, and proportions with advanced HIV disease between groups. HBsAg-positive individuals were more likely to be male ( $p < 0.001$ ). After one year of ART, 129 (6.6%) patients had died, 113 (5.8%) were LTFU and 63 (3.2%) transferred or withdrew from the study. One-year mortality was 6.5% (95% confidence interval 5.4-7.8%) in HIV-infected patients, 8.7% (4.9-15.2%) in HIV/HBV-coinfected ones with HBV VL <2000 IU/ml, and 8.2% (95% CI 4.4-15.2%) in HIV/HBV-coinfected patients with HBV VL >2000 IU/ml. In multivariable analyses, HBsAg-positivity was not associated with mortality ([Table](#)).

As opposed to Kouamé et al., we did not find a significant difference in mortality between HIV-infected individuals with active HBV infection and HBV-uninfected ones in southern Africa. We provide robust mortality estimates from primary care clinical settings in SSA, as we limited the risk of under-estimating death rates by systematically tracing patients LTFU (5). Although the burden of liver-related mortality due to HBV infection is high in SSA (6), mortality of patients initiating ART outside of clinical trials remains driven by HIV-associated causes. As low-income countries are starting to implement the “treat all” strategy for HIV infection, the impact of HBV infection on

clinical outcomes might become more evident. Therefore, long-term data from cohorts with intensive retention strategies will be crucial to inform monitoring of HIV/HBV-coinfected individuals in the near future.

Table. Risk factors for 1-year mortality, according to multivariable Cox proportional hazard regression analyses

	Deaths (%)	HR (95% CI)	p-value	aHR (95% CI)	p-value
<b>HBsAg (%)</b>					
negative	102/1673 (6.1)	Ref.		Ref.	
Positive	27/276 (9.8)	1.61 (1.05-2.45)	0.03	1.21 (0.74- 1.98)	0.45
<b>WHO stage (%)</b>					
1 or 2	50/1203 (4.2)	Ref.		Ref.	
3 or 4	79/732 (10.8)	2.69 (1.88-3.83)	<0.001	1.42 (0.93- 2.17)	0.10
<b>CD4 cell count (%)</b>					
≥200 cells/μl	41/973 (4.2)	Ref.		Ref.	
<200 cells/μl	71/640 (11.1)	2.76 (1.88-4.05)	<0.001	2.02 (1.33-3.07)	0.001
<b>BMI (%)</b>					
≥18.5 kg/m <sup>2</sup>	48/1275 (3.8)	Ref.		Ref.	
<18.5 kg/m <sup>2</sup>	67/519 (12.9)	3.60 (2.49-5.22)	<0.001	2.66 (1.76- 4.02)	<0.001
<b>Sex (%)</b>					
Female	52/1240 (4.2)	Ref.		Ref.	
Male	77/708 (10.9)	2.63 (1.85-3.74)	<0.001	1.72 (1.13- 2.62)	0.01
<b>Age (%)</b>					
<30 years	43/772 (5.6)	Ref.		Ref.	
≥30 years	86/1176 (7.3)	1.29 (0.89-1.85)	0.18	0.97 (0.63- 1.50)	0.89

HBsAg: Hepatitis B surface antigen, WHO: World Health Organization, BMI: body mass index

### Funding

This study was supported by the National Institute of Allergy and Infectious Diseases (Grant number 5U01-AI069924-05) and Fogarty International Center (Grant number 1K01TW009998) of the National Institutes of Health. GW was supported by an Ambizione-PROSPER fellowship (PZ00P3\_154730) from the Swiss National Science Foundation. The content is solely the responsibility of the authors and does not represent the official views of the funders.

### Conflict of Interest

All authors declare no conflict of interest.

## References

1. Kouame GM, Boyd A, Moh R, Badje A, Gabillard D, Ouattara E, et al. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication. *Clin Infect Dis*. 2018;66(1):112-20.
2. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. *Clin Infect Dis*. 2009;48(12):1763-71.
3. Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, et al. Cohort Profile: The international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. *Int J Epidemiol*. 2011.
4. Wandeler G, Musukuma K, Zurcher S, Vinikoor MJ, Llenas-Garcia J, Aly MM, et al. Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia. *PLoS One*. 2016;11(3):e0152043.
5. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. *PLoS One*. 2009;4(6):e5790.
6. WHO. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017.